According to the latest equity disclosure data from the Stock Exchange of Hong Kong, from September 12 to September 16, 2024, Hyloma Medical (03309.HK) chairman, CEO, and executive director Lin Shunchao increased his shareholding by acquiring 1.004 million shares at an average price per share of HK$2.0308-2.0571, with a total investment of approximately HK$2.05 million.
After the increase in shareholding, Lin Shunchao's latest shareholding is 691,616,553 shares, and the shareholding ratio has increased from 55.00% to 55.08%.
